{"name":"Polish Adult Leukemia Group","slug":"polish-adult-leukemia-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"A arm (CLAG-M)","genericName":"A arm (CLAG-M)","slug":"a-arm-clag-m","indication":"Acute myeloid leukemia (AML), particularly in relapsed/refractory or elderly patients","status":"phase_3"},{"name":"A arm (DA-90)","genericName":"A arm (DA-90)","slug":"a-arm-da-90","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia","status":"phase_3"},{"name":"B arm (DAC)","genericName":"B arm (DAC)","slug":"b-arm-dac","indication":"Acute myeloid leukemia (AML) in adult patients","status":"phase_3"},{"name":"B arm (FLAG-IDA)","genericName":"B arm (FLAG-IDA)","slug":"b-arm-flag-ida","indication":"Acute myeloid leukemia (AML), relapsed or refractory","status":"phase_3"}]}],"pipeline":[{"name":"A arm (CLAG-M)","genericName":"A arm (CLAG-M)","slug":"a-arm-clag-m","phase":"phase_3","mechanism":"CLAG-M is a chemotherapy regimen combining cladribine, cytarabine, and mitoxantrone designed to induce remission in acute myeloid leukemia.","indications":["Acute myeloid leukemia (AML), particularly in relapsed/refractory or elderly patients"],"catalyst":""},{"name":"A arm (DA-90)","genericName":"A arm (DA-90)","slug":"a-arm-da-90","phase":"phase_3","mechanism":"DA-90 is a monoclonal antibody targeting CD19.","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia"],"catalyst":""},{"name":"B arm (DAC)","genericName":"B arm (DAC)","slug":"b-arm-dac","phase":"phase_3","mechanism":"DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis.","indications":["Acute myeloid leukemia (AML) in adult patients"],"catalyst":""},{"name":"B arm (FLAG-IDA)","genericName":"B arm (FLAG-IDA)","slug":"b-arm-flag-ida","phase":"phase_3","mechanism":"FLAG-IDA is a chemotherapy combination regimen that uses fludarabine, cytarabine, and idarubicin to induce apoptosis in leukemic cells through DNA damage and inhibition of DNA synthesis.","indications":["Acute myeloid leukemia (AML), relapsed or refractory","Acute lymphoblastic leukemia (ALL), relapsed or refractory"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNa25TV0hJSm9TY1c0bV9MWE5fWGg4NF9iREMzV0h6bWoxb29YVjlpcGU3YUdNWkhuUHh0aThoUHFkMVc2RGZ5QW15RUlqS2VuQ0dDNnlWb01iLUJpQkJjMUtleklEMXhDeER1X29yRDFwTjVfbEI1aXZtR1A2Q0FqV0NnMWFrRllDWGc?oc=5","date":"2025-12-15","type":"pipeline","source":"Cancer Therapy Advisor","summary":"ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML - Cancer Therapy Advisor","headline":"ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}